Request More Information

Change: Change(%):
Volume: Open:
High: Low:
52Wk High: 52Wk Low:

Experts Commenting on This Company


Visit Company Website

View Company News

Exactech Inc.


Exactech Inc. is a pure-play orthopedic competitor gaining market share in the rapidly expanding global biomedical device industry. The company's products are used in the restoration of bones and joints that have deteriorated as a result of injury or disease such as arthritis. Exactech develops, manufactures, markets, distributes and sells its orthopedic implant devices, including knee, shoulder and hip implant systems, surgical instrumentation, spine products and biologic services to hospitals and physicians in the U.S. and over 30 markets in Europe, the Americas, Asia and the Pacific. International sales represent about 37% of total company sales.

The information provided below is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.

Expert Comments:

Mark Landy, Summer Street Research Partners (7/29/14) "Exactech Inc.'s Q2/14 revenues of $63.9M (+5%) were just above our forecast of $63.77M, ahead of the consensus forecast of $63.82M and just under the high end of the guidance range. . .results for Q2/14 were basically in line with expectations. . .we reiterate our Buy rating."

more comments

James Terwilliger, Benchmark Company (11/2/12) "We believe that Exactech Inc. posted strong Q3/12 results as revenue of $51.3M exceeded our $49.5M revenue estimate. . .we highlight that the Extremity product line posted revenue growth of 25%, the Hip product line posted revenue growth of 16% and that the Biologics and Spine business posted revenue growth of 10%. . .strong gross margins helped drive the upside surprise: the company posted Q3/12 gross margins of 70%. . .overall, we are encouraged that Exactech posted strong Q3/12 results. . . we reiterate our Buy rating."

William Plovanic, Canaccord Genuity (10/31/12) "We reiterate our Buy rating for Exactech Inc. following strong Q3/12 results. . .Hips continued to grow well above the market in both the U.S. and outside the U.S. . .we believe the stock is undervalued relative to its peers and a full product pipeline should drive continued growth."

Jeff Johnson, Baird Equity Research (10/31/12) "Exactech Inc. reported solid Q3/12 results last night, with organic growth of 10% above our +9.4% projection and EPS of $0.19 beating our consensus-matching $0.17. . .the company has grown revenue ~16% annually over the past 10 years, or roughly 1.52x the industry during this time, and we believe new products that are set to launch over the next several months, ongoing sales force investments and international selling changes should help this above-market growth continue in 2012 and beyond."

fewer comments
Due to permission requirements, not all quotes are shown.

Exactech Inc. Content

Back to Top